PMID,Title,Publication Date,Non-Academic Authors,Corresponding Author Email
40053698,Prospective Evaluation of Structure-Based Simulations Reveal Their Ability to Predict the Impact of Kinase Mutations on Inhibitor Binding.,2025,"Aziz M Rangwala (Department of Pharmacological Sciences, Stony Brook University Medical School, Stony Brook, New York 11794, United States.); Joseph P Bluck (Structural Biology & Computational Design, Research and Development, Pharmaceuticals, Bayer AG, 13342 Berlin, Germany.); Clara D Christ (Structural Biology & Computational Design, Research and Development, Pharmaceuticals, Bayer AG, 13342 Berlin, Germany.); Markus A Seeliger (Department of Pharmacological Sciences, Stony Brook University Medical School, Stony Brook, New York 11794, United States.)",Not Available
40053572,Hafnium-Doped Prussian Blue Nanoparticles with Homologous Tumor Targeting and Magnetic Resonance Imaging Ability for Enhanced Tumor Radiotherapy via Photothermal Therapy and Hypoxia Relief.,2025,"Ye Kuang (Fujian Key Laboratory of Drug Target Discovery and Structural and Functional Research, School of Pharmacy, Fujian Medical University, Fuzhou 350122, China.); Yufang Chen (Fujian Key Laboratory of Drug Target Discovery and Structural and Functional Research, School of Pharmacy, Fujian Medical University, Fuzhou 350122, China.); Xinying Liu (Fujian Key Laboratory of Drug Target Discovery and Structural and Functional Research, School of Pharmacy, Fujian Medical University, Fuzhou 350122, China.); Baohui Liu (Fujian Key Laboratory of Drug Target Discovery and Structural and Functional Research, School of Pharmacy, Fujian Medical University, Fuzhou 350122, China.); Yu Duan (Fujian Key Laboratory of Drug Target Discovery and Structural and Functional Research, School of Pharmacy, Fujian Medical University, Fuzhou 350122, China.); Chaowei Hong (Fujian Key Laboratory of Drug Target Discovery and Structural and Functional Research, School of Pharmacy, Fujian Medical University, Fuzhou 350122, China.); Changmai Chen (Fujian Key Laboratory of Drug Target Discovery and Structural and Functional Research, School of Pharmacy, Fujian Medical University, Fuzhou 350122, China.); Wei Chen (Fujian Key Laboratory of Drug Target Discovery and Structural and Functional Research, School of Pharmacy, Fujian Medical University, Fuzhou 350122, China.)",Not Available
40053482,c-MET tyrosine kinase inhibitors reverse multidrug resistance in breast cancer cells by targeting ABCG2 transporter.,2025,"Fatemeh Mosaffa (Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.); Luciano Saso (Department of Physiology and Pharmacology ""Vittorio Erspamer"", Sapienza University of Rome, P. le Aldo Moro 5, 00185 Rome, Italy.)",Not Available
40053076,Clofazimine enhances anti-PD-1 immunotherapy in glioblastoma by inhibiting Wnt6 signaling and modulating the tumor immune microenvironment.,2025,"Weiping Li (Department of Pharmacology, Shanxi Medical University Fenyang College, Fenyang, 032200, China.); Zhengbao Zhao (Department of Pharmacy, Shanxi Medical University, Taiyuan, 030001, China.); Tingli Qu (Department of Pharmacy, Shanxi Medical University, Taiyuan, 030001, China.)",Not Available
40052837,Treatment of Multiple Myeloma in Patients Refractory to Daratumumab/Anti-CD38 Monoclonal Antibodies: A Systematic Review.,2025,"Chia Jie Tan (Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, Utah, USA.); Dylan Kacerek (Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, Utah, USA.); Nathorn Chaiyakunapruk (Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, Utah, USA.)",Not Available
40051496,Metabolic crossroads: unravelling immune cell dynamics in gastrointestinal cancer drug resistance.,2025,"Lakkakula Suhasini Sahithi (Department of Biotechnology, Guru Ghasidas Vishwavidyalaya, Bilaspur 495009, India.); Tuneer Khelkar (Department of Botany and Biotechnology, Govt. Kaktiya P G College, Jagdalpur 494001, India.)",Not Available
40050889,Repurposing pitavastatin and atorvastatin to overcome chemoresistance of metastatic colorectal cancer under high glucose conditions.,2025,"Wei-Ming Cheng (Program in Molecular Medicine, College of Life Sciences, National Yang Ming Chiao Tung University, Taipei, 112, Taiwan.); Po-Chen Li (Institute of Biopharmaceutical Sciences, College of Pharmaceutical Sciences, National Yang Ming Chiao Tung University, Taipei, 112, Taiwan.); Minh Tran-Binh Nguyen (Institute of Biopharmaceutical Sciences, College of Pharmaceutical Sciences, National Yang Ming Chiao Tung University, Taipei, 112, Taiwan.); Yu-Teng Lin (Institute of Biopharmaceutical Sciences, College of Pharmaceutical Sciences, National Yang Ming Chiao Tung University, Taipei, 112, Taiwan.); Yu-Tang Huang (Institute of Biopharmaceutical Sciences, College of Pharmaceutical Sciences, National Yang Ming Chiao Tung University, Taipei, 112, Taiwan.); Tai-Shan Cheng (Institute of Biopharmaceutical Sciences, College of Pharmaceutical Sciences, National Yang Ming Chiao Tung University, Taipei, 112, Taiwan.); Thi-Huong Nguyen (Institute of Biopharmaceutical Sciences, College of Pharmaceutical Sciences, National Yang Ming Chiao Tung University, Taipei, 112, Taiwan.); Thu-Ha Tran (Institute of Biopharmaceutical Sciences, College of Pharmaceutical Sciences, National Yang Ming Chiao Tung University, Taipei, 112, Taiwan.); Tzu-Yi Huang (Program in Molecular Medicine, College of Life Sciences, National Yang Ming Chiao Tung University, Taipei, 112, Taiwan.); Thu-Huyen Hoang (Institute of Biopharmaceutical Sciences, College of Pharmaceutical Sciences, National Yang Ming Chiao Tung University, Taipei, 112, Taiwan.); Sin-Yu Chen (Institute of Biopharmaceutical Sciences, College of Pharmaceutical Sciences, National Yang Ming Chiao Tung University, Taipei, 112, Taiwan.); Yi-Shiou Chiou (Master Degree Program in Toxicology, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, 807, Taiwan.); Peter Mu-Hsin Chang (Institute of Biopharmaceutical Sciences, College of Pharmaceutical Sciences, National Yang Ming Chiao Tung University, Taipei, 112, Taiwan.); Yu-Feng Hu (Institute of Biopharmaceutical Sciences, College of Pharmaceutical Sciences, National Yang Ming Chiao Tung University, Taipei, 112, Taiwan.); Chi-Ying F Huang (Program in Molecular Medicine, College of Life Sciences, National Yang Ming Chiao Tung University, Taipei, 112, Taiwan. cyhuang5@nycu.edu.tw.)",Not Available
40050048,Cell-intrinsic PD-L1 signaling drives immunosuppression by myeloid-derived suppressor cells through IL-6/Jak/Stat3 in PD-L1-high lung cancer.,2025,"Hanbyeol Kim (Department of Pharmacology, Seoul National University College of Medicine, Seoul, Korea (the Republic of).); Yingying Li (Department of Pharmacology, Seoul National University College of Medicine, Seoul, Korea (the Republic of).); Soo Hyun Lee (Department of Pharmacology, Seoul National University College of Medicine, Seoul, Korea (the Republic of).); Chul-Hwan Lee (Department of Pharmacology, Seoul National University College of Medicine, Seoul, Korea (the Republic of).)",Not Available
40049495,Time-performance relationship and the associated mechanism of tumor drug-efflux pump P-glycoprotein reversal induced by mild photothermal therapy.,2025,"Qin Shi (School of Pharmacy, Jiangsu Medical College, Yancheng 224005, China. Electronic address: sqzyf1314@163.com.); Jiyuan Zhou (Department of Pharmaceutics, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, China.); Jiejie Cheng (Department of Pharmaceutics, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, China.); Tingjie Yin (Department of Pharmaceutics, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, China. Electronic address: cookey_89ytj@163.com.)",Not Available
40049296,Strategic advancements in targeting the PI3K/AKT/mTOR pathway for Breast cancer therapy.,2025,"Sravani Ramisetty (Department of Medical Oncology & Therapeutics Research, Beckman Research Institute of City of Hope, Comprehensive Cancer Center and National Medical Center, Duarte, CA 91010, USA.); Prakash Kulkarni (Department of Medical Oncology & Therapeutics Research, Beckman Research Institute of City of Hope, Comprehensive Cancer Center and National Medical Center, Duarte, CA 91010, USA.); Ravi Salgia (Department of Medical Oncology & Therapeutics Research, Beckman Research Institute of City of Hope, Comprehensive Cancer Center and National Medical Center, Duarte, CA 91010, USA.); Sharad S Singhal (Department of Medical Oncology & Therapeutics Research, Beckman Research Institute of City of Hope, Comprehensive Cancer Center and National Medical Center, Duarte, CA 91010, USA. Electronic address: ssinghal@coh.org.)",Not Available
40049295,Therapeutic targets in the Wnt signaling pathway: Treating cancer with specificity.,2025,"Jiaxi Zhang (Jiangsu Key Laboratory for Molecular and Medical Biotechnology, School of Life Science, Nanjing Normal University, Nanjing 210023, China.); Haochuan Guo (Jiangsu Key Laboratory for Molecular and Medical Biotechnology, School of Life Science, Nanjing Normal University, Nanjing 210023, China.); Chengxuan Gong (Jiangsu Key Laboratory for Molecular and Medical Biotechnology, School of Life Science, Nanjing Normal University, Nanjing 210023, China.); Jie Shen (Jiangsu Key Laboratory for Molecular and Medical Biotechnology, School of Life Science, Nanjing Normal University, Nanjing 210023, China.); Guijie Jiang (Jiangsu Key Laboratory for Molecular and Medical Biotechnology, School of Life Science, Nanjing Normal University, Nanjing 210023, China.); Tingming Liang (Jiangsu Key Laboratory for Molecular and Medical Biotechnology, School of Life Science, Nanjing Normal University, Nanjing 210023, China. Electronic address: tmliang@njnu.edu.cn.)",Not Available
40049050,The role of VEGF in Cancer angiogenesis and tumorigenesis: Insights for anti-VEGF therapy.,2025,"Zijun Shi (School of Life Sciences, Jiangsu University, Zhenjiang 212013, China.); Mengmeng Kuai (School of Life Sciences, Jiangsu University, Zhenjiang 212013, China.); Baohua Li (School of Life Sciences, Jiangsu University, Zhenjiang 212013, China.); Carlos Frimpong Akowuah (School of Life Sciences, Jiangsu University, Zhenjiang 212013, China.); Zhenyu Wang (School of Life Sciences, Jiangsu University, Zhenjiang 212013, China.); Ye Pan (School of Life Sciences, Jiangsu University, Zhenjiang 212013, China.); Min Tang (School of Life Sciences, Jiangsu University, Zhenjiang 212013, China.); Peng Lü (School of Life Sciences, Jiangsu University, Zhenjiang 212013, China; Affiliated Hospital of Jiangsu University, Zhenjiang 212013, China. Electronic address: penglu@ujs.edu.cn.)",Not Available
40048984,Targeted mitochondrial therapy for pancreatic cancer.,2025,"Xinya Zhao (Department of Pharmacy, First Affiliated Hospital of Dalian Medical University, Dalian, 116011, China; College of Pharmacy, Dalian Medical University, Dalian, 116044, China.); Guoyu Wu (Department of Pharmacy, First Affiliated Hospital of Dalian Medical University, Dalian, 116011, China.); Xufeng Tao (Department of Pharmacy, First Affiliated Hospital of Dalian Medical University, Dalian, 116011, China. Electronic address: taoxufeng.2008@163.com.); Deshi Dong (Department of Pharmacy, First Affiliated Hospital of Dalian Medical University, Dalian, 116011, China. Electronic address: dongdeshi@dmu.edu.cn.)",Not Available
40048957,The combination of flaxseed lignans and PD-1/ PD-L1 inhibitor inhibits breast cancer growth via modulating gut microbiome and host immunity.,2025,"Hao Wu (Heilongjiang Clinical Research Center for Breast Cancer, Harbin Medical University Cancer Hospital, Harbin, China; Genomics Research Center, State Key Laboratory of Biomedicine-Pharmaceutics of China, College of Pharmacy, Harbin Medical University, Harbin, China. Electronic address: 3345@hrbmu.edu.cn.); Xing-Hua Zhang (Genomics Research Center, State Key Laboratory of Biomedicine-Pharmaceutics of China, College of Pharmacy, Harbin Medical University, Harbin, China; Key Laboratory of Gut Microbiota and Pharmacogenomics of Heilongjiang Province, Harbin Medical University, Harbin, China; HMU-UCCSM Centre for Infection and Genomics, Harbin Medical University, Harbin, China; National Key Laboratory of Frigid Zone Cardiovascular Diseases, Harbin 150081, China.); Huidi Liu (Genomics Research Center, State Key Laboratory of Biomedicine-Pharmaceutics of China, College of Pharmacy, Harbin Medical University, Harbin, China; Key Laboratory of Gut Microbiota and Pharmacogenomics of Heilongjiang Province, Harbin Medical University, Harbin, China; HMU-UCCSM Centre for Infection and Genomics, Harbin Medical University, Harbin, China; National Key Laboratory of Frigid Zone Cardiovascular Diseases, Harbin 150081, China; Department of Biochemistry and Molecular Biology, University of Calgary, Calgary, AB, Canada.); Hong-Da Tian (Genomics Research Center, State Key Laboratory of Biomedicine-Pharmaceutics of China, College of Pharmacy, Harbin Medical University, Harbin, China; Key Laboratory of Gut Microbiota and Pharmacogenomics of Heilongjiang Province, Harbin Medical University, Harbin, China; HMU-UCCSM Centre for Infection and Genomics, Harbin Medical University, Harbin, China; National Key Laboratory of Frigid Zone Cardiovascular Diseases, Harbin 150081, China.); Jin-Ru Lai (Genomics Research Center, State Key Laboratory of Biomedicine-Pharmaceutics of China, College of Pharmacy, Harbin Medical University, Harbin, China; Key Laboratory of Gut Microbiota and Pharmacogenomics of Heilongjiang Province, Harbin Medical University, Harbin, China; HMU-UCCSM Centre for Infection and Genomics, Harbin Medical University, Harbin, China; National Key Laboratory of Frigid Zone Cardiovascular Diseases, Harbin 150081, China.); Gui-Rong Liu (Genomics Research Center, State Key Laboratory of Biomedicine-Pharmaceutics of China, College of Pharmacy, Harbin Medical University, Harbin, China; Key Laboratory of Gut Microbiota and Pharmacogenomics of Heilongjiang Province, Harbin Medical University, Harbin, China; HMU-UCCSM Centre for Infection and Genomics, Harbin Medical University, Harbin, China; National Key Laboratory of Frigid Zone Cardiovascular Diseases, Harbin 150081, China.); Shu-Lin Liu (Genomics Research Center, State Key Laboratory of Biomedicine-Pharmaceutics of China, College of Pharmacy, Harbin Medical University, Harbin, China; Key Laboratory of Gut Microbiota and Pharmacogenomics of Heilongjiang Province, Harbin Medical University, Harbin, China; HMU-UCCSM Centre for Infection and Genomics, Harbin Medical University, Harbin, China; National Key Laboratory of Frigid Zone Cardiovascular Diseases, Harbin 150081, China; Department of Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, AB, Canada. Electronic address: slliu@hrbmu.edu.cn.)",Not Available
40048112,"Inhibitory effects of carbohydrazide indole derivative on micro-blood vessel growth using ex vivo, in vivo, and in vitro assays.",2025,"Bayan Jamal Khaleel (Department of Pharmacology, College of Medicine, Al-Nahrain University, Baghdad, Iraq.); Hayder Ridha-Salman (College of Pharmacy, Al-Mustaqbal University, Hillah, 51001, Babylon, Iraq. hayder80.ridha@gmail.com.); Haitham Mahmood Kadhim (Department of Pharmacology and Toxicology, College of Pharmacy, Al-Nahrain University, Baghdad, Iraq.); Omeed M Hassan (Department of Pharmaceutical Chemistry, College of Pharmacy, University of Kirkuk, Kirkuk, Iraq.); Ammar Kubba (Department of Pharmaceutical Chemistry, College of Pharmacy, University of Baghdad, Baghdad, Iraq.); Hayder B Sahib (College of Pharmacy, Al-Mustaqbal University, Hillah, 51001, Babylon, Iraq.)",Not Available
40048009,Polycomb repressive complex 2 (PRC2) pathway's role in cancer cell plasticity and drug resistance.,2025,"Pouya Goleij (Immunology Board for Transplantation and Cell-Based Therapeutics (Immunotact), Universal Scientific Education and Research Network (USERN), Tehran, Iran. medgenetic.1991@gmail.com.); Pantea Majma Sanaye (School of Pharmacy, Zanjan University of Medical Sciences, Zanjan, 4513956184, Iran.); Maria Daglia (Department of Pharmacy, University of Naples ""Federico II"", Via D. Montesano 49, 80131, Naples, Italy.); Haroon Khan (Department of Pharmacy, Faculty of Chemical and Life Sciences, Abdul Wali Khan University Mardan, Mardan, 23200, Pakistan. haroonkhan@awkum.edu.pk.)",Not Available
40047858,Natural compounds as regulators of miRNAs: exploring a new avenue for treating brain cancer.,2025,"Ahmed S Doghish (Department of Biochemistry, Faculty of Pharmacy, Badr University in Cairo (BUC), Badr City, Cairo, 11829, Egypt. ahmed_doghish@azhar.edu.eg.); Walaa A El-Dakroury (Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Badr University in Cairo (BUC), Badr City, Cairo, 11829, Egypt.); Ahmed I Abulsoud (Biochemistry and Molecular Biology Department, Faculty of Pharmacy (Boys), Al-Azhar University, Nasr City, Cairo, 11231, Egypt.); Nourhan M Abdelmaksoud (Department of Biochemistry, Faculty of Pharmacy, Heliopolis University, Cairo, 11785, Egypt.); Shaza H Aly (Department of Pharmacognosy, Faculty of Pharmacy, Badr University in Cairo (BUC), Badr City, Cairo, 11829, Egypt.); Osama A Mohammed (Department of Pharmacology, College of Medicine, University of Bisha, Bisha, 61922, Saudi Arabia.); Mustafa Ahmed Abdel-Reheim (Department of Pharmacology, College of Pharmacy, Shaqra University, Shaqra, 11961, Saudi Arabia. m.ahmed@su.edu.sa.); Mohamed Bakr Zaki (Department of Biochemistry, Faculty of Pharmacy, University of Sadat City, Sadat City, Menoufia, 32897, Egypt.); Nehal I Rizk (Department of Biochemistry, Faculty of Pharmacy and Drug Technology, Egyptian Chinese University, Cairo, 11786, Egypt.); Esraa M Mosalam (Biochemistry Department, Faculty of Pharmacy, Menoufia University, Shebin El-Kom, 32511, Egypt.); Sherif S Abdel Mageed (Pharmacology and Toxicology Department, Faculty of Pharmacy, Badr University in Cairo (BUC), Badr City, Cairo, 11829, Egypt.)",Not Available
40047275,Synthesis and Antitumor Evaluation of a Novel Class of Chalcone Mannich Base Derivatives.,2025,"Bing He (College of Pharmacy, Anhui University of Chinese Medicine, Hefei, China.); Hong-Zhou Tan (College of Pharmacy, Anhui University of Chinese Medicine, Hefei, China.); Cheng-Bo Liu (College of Pharmacy, Anhui University of Chinese Medicine, Hefei, China.); Hong Wu (College of Pharmacy, Anhui University of Chinese Medicine, Hefei, China.); Li-Qin He (College of Pharmacy, Anhui University of Chinese Medicine, Hefei, China.)",Not Available
40046748,"{'i': ['in vitro', 'in vivo'], '#text': 'Dual inhibitor of MDM2 and NFAT1 for experimental therapy of breast cancer:  and  anticancer activities and newly discovered effects on cancer metabolic pathways.'}",2025,"Wei Wang (Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX, United States.); Sayantap Datta (Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX, United States.); Abigail Alley (Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX, United States.); Meheret Tadesse (Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX, United States.); Xinshi Wang (Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX, United States.); Ruiwen Zhang (Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX, United States.)",Not Available
40046407,Combining JAK Inhibitors with Immune Checkpoint Inhibitors: Overcoming Resistance in Cancer Treatment.,2025,Hai-Jing Zhong (State Key Laboratory of Bioactive Molecules and Druggability Assessment International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education (MOE) of China College of Pharmacy Jinan University Guangzhou China.),Not Available
40045459,"{'sup': 'V600E', '#text': 'BRAF-PROTAC versus inhibitors in melanoma cells: Deep transcriptomic characterisation.'}",2025,"Zakaria Y Abd Elmageed (Department of Pharmacology, Edward Via College of Osteopathic Medicine, University of Louisiana, Monroe, Louisiana, USA.); Mourad Zerfaoui (Center for ViroScience and Cure, Department of Pediatrics, Laboratory of Biochemical Pharmacology, Emory University School of Medicine, Atlanta, Georgia, USA.)",Not Available
40044797,New insights of cerium oxide nanoparticles in head and neck cancer treatment.,2025,"Elif Tarakci (Climate Change and Life Sciences, Biotechnology Research Group, TUBITAK-Marmara Research Center, 41470, Gebze, Kocaeli, Turkey.); Sahra Esmkhani (Climate Change and Life Sciences, Biotechnology Research Group, TUBITAK-Marmara Research Center, 41470, Gebze, Kocaeli, Turkey.); Jamila Bayramova (Climate Change and Life Sciences, Biotechnology Research Group, TUBITAK-Marmara Research Center, 41470, Gebze, Kocaeli, Turkey.); Feride Melisa Bilgin (Climate Change and Life Sciences, Biotechnology Research Group, TUBITAK-Marmara Research Center, 41470, Gebze, Kocaeli, Turkey.); Kubra Kidik (Climate Change and Life Sciences, Biotechnology Research Group, TUBITAK-Marmara Research Center, 41470, Gebze, Kocaeli, Turkey.); Ahsen Morva Yilmaz (Climate Change and Life Sciences, Biotechnology Research Group, TUBITAK-Marmara Research Center, 41470, Gebze, Kocaeli, Turkey.); Filiz Kaya (Climate Change and Life Sciences, Biotechnology Research Group, TUBITAK-Marmara Research Center, 41470, Gebze, Kocaeli, Turkey.); Digdem Aktoprakligil Aksu (Climate Change and Life Sciences, Biotechnology Research Group, TUBITAK-Marmara Research Center, 41470, Gebze, Kocaeli, Turkey.); Hilal Yazici (Climate Change and Life Sciences, Biotechnology Research Group, TUBITAK-Marmara Research Center, 41470, Gebze, Kocaeli, Turkey. hilal.yazici@tubitak.gov.tr.)",Not Available
40044682,MiR-769-5p of macrophage exosomes induced by GRP78 promotes stemness and chemoresistance in colorectal cancer.,2025,"Jinmiao Tian (Key Laboratory of Chemical Biology and Molecular Engineering of the National Ministry of Education, Institute of Biotechnology, Shanxi University, Taiyuan, 030006, China.); Xiaxia Fan (Key Laboratory of Chemical Biology and Molecular Engineering of the National Ministry of Education, Institute of Biotechnology, Shanxi University, Taiyuan, 030006, China.); Zhuoyu Li (Key Laboratory of Chemical Biology and Molecular Engineering of the National Ministry of Education, Institute of Biotechnology, Shanxi University, Taiyuan, 030006, China. lzy@sxu.edu.cn.)",Not Available
40044105,"piRNAs in leukemogenesis: Mechanisms, biomarkers, and therapeutic implications.",2025,"Gaurav Gupta (Centre for Research Impact & Outcome, Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab 140401, India; Centre of Medical and Bio-allied Health Sciences Research, Ajman University, Ajman, United Arab Emirates.); Muhammad Afzal (Department of Pharmaceutical Sciences, Pharmacy Program, Batterjee Medical College, P.O. Box 6231, Jeddah 21442, Saudi Arabia.); Ahsas Goyal (Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, India.); Mohit Rana (Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, India.); Kavita Goyal (Department of Biotechnology, Graphic Era (Deemed to be University), Clement Town, Dehradun 248002, India. Electronic address: kavita.g01@outlook.com.); Sachin Kumar Singh (School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab 144411, India.)",Not Available
40043463,Targeting and engineering biomarkers for prostate cancer therapy.,2025,"Dhirodatta Senapati (KIIT School of Pharmacy, KIIT (Deemed to be University), Bhubaneswar, Odisha, India. Electronic address: dhirodatta.senapati@kims.ac.in.); Santosh Kumar Sahoo (GITAM School of Pharmacy, GITAM (Deemed to be University), Visakhapatnam, Andhra Pradesh, 530045, India.); Bhabani Shankar Nayak (KIIT School of Pharmacy, KIIT (Deemed to be University), Bhubaneswar, Odisha, India.); Gopal C Kundu (Kalinga Institute of Medical Sciences (KIMS), KIIT (Deemed to be University), Bhubaneswar, 751024, India; School of Biotechnology, KIIT (Deemed to be University), Bhubaneswar, 751024, India.); Subrat Kumar Bhattamisra (Department of Pharmacy, School of Health Science, Central University of South Bihar, Bihar, India.)",Not Available
40043386,"Novel inhibitors of oncogenic Wnt/TCF-4/β-catenin signaling pathway: Design, synthesis, molecular docking studies and apoptosis inducing activity of pyrimidothiazino-, dihydropyrimidotriazepino- and 1,3,4-thiadiazolopyrimido-indole hybrids.",2025,"Mai A E Mourad (Medicinal Chemistry Department, Faculty of Pharmacy, Port-Said University, Port-Said 42511, Egypt; Medicinal Chemistry Department, Pharmacology and Toxicology Department, Faculty of Pharmacy, East Port-Said National University, Port-Said, Egypt. Electronic address: mai.mourad@pharm.psu.edu.eg.); Ahmed A E Mourad (Pharmacology and Toxicology Department, Faculty of Pharmacy, Port-Said University, Port-Said 42511, Egypt; Medicinal Chemistry Department, Pharmacology and Toxicology Department, Faculty of Pharmacy, East Port-Said National University, Port-Said, Egypt. Electronic address: ahmed.mourad@pharm.psu.edu.eg.); Ayman Abo Elmaaty (Medicinal Chemistry Department, Faculty of Pharmacy, Port-Said University, Port-Said 42511, Egypt. Electronic address: ayman.mohamed@pharm.psu.edu.eg.); Amal Hofni (Department of Pharmacology and Toxicology, Faculty of Pharmacy, South Valley University, Qena 83523, Egypt. Electronic address: amal.gaber@svu.edu.eg.); Ahmed E Khodir (Department of Pharmacology, Faculty of Pharmacy, Horus University, New Damietta 34518, Egypt. Electronic address: akhodir@horus.edu.eg.); Esam M Aboubakr (Department of Pharmacology and Toxicology, Faculty of Pharmacy, South Valley University, Qena 83523, Egypt. Electronic address: esam_pharma@svu.edu.eg.); Wagdy M Eldehna (Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh 33516, Egypt; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Pharos University in Alexandria; Canal El Mahmoudia St., Alexandria 21648, Egypt.); Ahmed A Al-Karmalawy (Department of Pharmaceutical Chemistry, College of Pharmacy, The University of Mashreq, Baghdad 10023, Iraq; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Horus University-Egypt, New Damietta 34518, Egypt. Electronic address: akarmalawy@horus.edu.eg.)",Not Available
40043112,Differential regulation of BAX and BAK apoptotic activity revealed by small molecules.,2025,"Guillaume Lessene (Department of Biochemistry and Pharmacology, University of Melbourne, Parkville, Victoria, Australia.)",Not Available
40041949,Oxygen-Releasing Nanodroplets Relieve Intratumoral Hypoxia and Potentiate Photodynamic Therapy in 3D Head and Neck Cancer Spheroids.,2025,"Jason Cook (NanoHybrids, Inc., Acton, Massachusetts 01720, United States.)",Not Available
40041899,"{'i': 'β', '#text': 'Natural product mediated mesenchymal-epithelial remodeling by covalently binding ENO1 to degrade m6A modified -catenin mRNA.'}",2025,"Tianyang Chen (State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 300353, China.); Guangju Liu (State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 300353, China.); Sisi Chen (State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 300353, China.); Fengyuan Zhang (State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 300353, China.); Shuoqian Ma (State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 300353, China.); Yongping Bai (State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 300353, China.); Quan Zhang (State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 300353, China.)",Not Available
40040956,Biomimetic Atorvastatin Self-Assembled Nanomedicine Inhibits the Cyclooxygenase-2/Prostaglandin E2 Pathway Enhanced Photothermal and Antitumor Immunity.,2025,"Min Zhou (Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha 410011, China.); Ruyue Han (Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha 410011, China.); Wenjie Xu (Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha 410011, China.); Xinyan Hao (Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha 410011, China.); Yanjin Peng (Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha 410011, China.); Yucheng Tang (Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha 410011, China.); Pengcheng Sun (Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha 410011, China.); Tiantian Tang (Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha 410011, China.); Junyong Wu (Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha 410011, China.); Daxiong Xiang (Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha 410011, China.)",Not Available
40040813,Targeting FAK improves the tumor uptake of antibody-drug conjugates to strengthen the anti-cancer responses.,2025,"Baoyuan Zhang (InxMed (Shanghai) Co., Ltd., Shanghai, China.); Jiaming Gao (InxMed (Shanghai) Co., Ltd., Shanghai, China.); Shiqiang Lu (InxMed (Shanghai) Co., Ltd., Shanghai, China.); Ran Pang (InxMed (Shanghai) Co., Ltd., Shanghai, China.); Natasha Qin (InxMed (Shanghai) Co., Ltd., Shanghai, China.); Leo Liu (InxMed (Shanghai) Co., Ltd., Shanghai, China.); Zaiqi Wang (InxMed (Shanghai) Co., Ltd., Shanghai, China.)",Not Available
40038780,Anti-TGF-β/PD-L1 bispecific antibody synergizes with radiotherapy to enhance antitumor immunity and mitigate radiation-induced pulmonary fibrosis.,2025,"Jing Zhang (Wuhan YZY Biopharma Co., Ltd., Biolake, C2-1, No.666 Gaoxin Road, Wuhan, 430075, China.); Pengfei Zhou (Wuhan YZY Biopharma Co., Ltd., Biolake, C2-1, No.666 Gaoxin Road, Wuhan, 430075, China.)",Not Available
40038413,Targeted degradation of CDK4/6 by LA-CB1 inhibits EMT and suppresses tumor growth in orthotopic breast cancer.,2025,"Jingliang He (Jiangsu Key Laboratory of Marine Pharmaceutical Compound Screening, College of Pharmacy, Jiangsu Ocean University, Lianyungang, 222005, China.); Siyi Zhang (Jiangsu Key Laboratory of Marine Pharmaceutical Compound Screening, College of Pharmacy, Jiangsu Ocean University, Lianyungang, 222005, China.); Qi Gao (Jiangsu Key Laboratory of Marine Pharmaceutical Compound Screening, College of Pharmacy, Jiangsu Ocean University, Lianyungang, 222005, China.); Lan Zhu (Cancer Center and Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI, 53226, USA.); Ningyang Xu (Cancer Center and Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI, 53226, USA.); Zhongke Hu (Jiangsu Key Laboratory of Marine Pharmaceutical Compound Screening, College of Pharmacy, Jiangsu Ocean University, Lianyungang, 222005, China.); Xingyu Zhang (Jiangsu Key Laboratory of Marine Pharmaceutical Compound Screening, College of Pharmacy, Jiangsu Ocean University, Lianyungang, 222005, China.); Shaojie Ma (Jiangsu Key Laboratory of Marine Pharmaceutical Compound Screening, College of Pharmacy, Jiangsu Ocean University, Lianyungang, 222005, China.); Xiujun Wang (Jiangsu Key Laboratory of Marine Pharmaceutical Compound Screening, College of Pharmacy, Jiangsu Ocean University, Lianyungang, 222005, China.); Bin Liu (Jiangsu Key Laboratory of Marine Pharmaceutical Compound Screening, College of Pharmacy, Jiangsu Ocean University, Lianyungang, 222005, China. liubin@jou.edu.cn.); Wei Liu (Cancer Center and Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI, 53226, USA. weiliu@mcw.edu.)",Not Available
40038300,Inhibition of the STAT3/Fanconi anemia axis is synthetic lethal with PARP inhibition in breast cancer.,2025,"Eddy Pasquier (CRCM, INSERM, CNRS, Institut Paoli-Calmettes, Aix-Marseille University, Reverse Molecular Pharmacology in Pediatric Oncology, Marseille, France.)",Not Available
40038250,Circulating mitochondrial DNA promotes M2 polarization of tumor associated macrophages and HCC resistance to sorafenib.,2025,"Qi Yang (School of Life Sciences, School of Pharmacy, Henan University, Kaifeng, Henan, 475004, China.); Mengmeng Cui (Laboratory of Cancer Biomarkers and Liquid Biopsy, School of Pharmacy, Henan University, Kaifeng, Henan, 475004, China.); Jiaxin Wang (Laboratory of Cancer Biomarkers and Liquid Biopsy, School of Pharmacy, Henan University, Kaifeng, Henan, 475004, China.); Yuan Zhao (School of Life Sciences, School of Pharmacy, Henan University, Kaifeng, Henan, 475004, China.); Weitao Yin (School of Life Sciences, School of Pharmacy, Henan University, Kaifeng, Henan, 475004, China.); Ziqian Liao (Laboratory of Cancer Biomarkers and Liquid Biopsy, School of Pharmacy, Henan University, Kaifeng, Henan, 475004, China.); Yixuan Liang (Laboratory of Cancer Biomarkers and Liquid Biopsy, School of Pharmacy, Henan University, Kaifeng, Henan, 475004, China.); Zhixiong Jiang (Laboratory of Cancer Biomarkers and Liquid Biopsy, School of Pharmacy, Henan University, Kaifeng, Henan, 475004, China.); Yujia Li (School of Life Sciences, School of Pharmacy, Henan University, Kaifeng, Henan, 475004, China.); Jinrong Guo (School of Life Sciences, School of Pharmacy, Henan University, Kaifeng, Henan, 475004, China.); Lixia Qi (Laboratory of Cancer Biomarkers and Liquid Biopsy, School of Pharmacy, Henan University, Kaifeng, Henan, 475004, China.); Jiaxing Chen (Laboratory of Cancer Biomarkers and Liquid Biopsy, School of Pharmacy, Henan University, Kaifeng, Henan, 475004, China.); Jing Zhao (School of Life Sciences, School of Pharmacy, Henan University, Kaifeng, Henan, 475004, China.); Dengke Bao (School of Life Sciences, School of Pharmacy, Henan University, Kaifeng, Henan, 475004, China. bdkmydy12004@126.com.); Zhi-Xiang Xu (School of Life Sciences, School of Pharmacy, Henan University, Kaifeng, Henan, 475004, China. zhixiangxu08@gmail.com.)",Not Available
40038236,High baseline levels of PD-L1 reduce the heterogeneity of immune checkpoint signature and sensitize anti-PD1 therapy in lung and colorectal cancers.,2025,"Peng Fan (National Center of Technology Innovation for Biopharmaceuticals, Suzhou Biomedical Industry Innovation Center, Suzhou, China.); Jiajie Kuai (Institute of Clinical Pharmacology, Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anti-inflammatory and Immune Medicine, Anhui Medical University, Hefei, China.); Wei Xu (New Drug Biology and Translational Medicine, Innovent Biologics Inc., Suzhou, China.); Yuhui Huang (National Center of Technology Innovation for Biopharmaceuticals, Suzhou Biomedical Industry Innovation Center, Suzhou, China. huangyh@suda.edu.cn.)",Not Available
40037887,Super Methotrexate-resistant Osteosarcoma Cells Retain Their Sensitivity to Recombinant Methioninase: Targeting Methionine Addiction to Overcome Extreme Cancer-Chemotherapy Resistance.,2025,"Yusuke Aoki (AntiCancer Inc, San Diego, CA, U.S.A.; yaoki0630@gmail.com.); Qinghong Han (AntiCancer Inc, San Diego, CA, U.S.A.); Yutaro Kubota (AntiCancer Inc, San Diego, CA, U.S.A.); Noriyuki Masaki (AntiCancer Inc, San Diego, CA, U.S.A.); Michael Bouvet (Department of Surgery, University of California, San Diego, La Jolla, CA, U.S.A.); Robert M Hoffman (AntiCancer Inc, San Diego, CA, U.S.A.; all@anticancer.com.)",Not Available
40037884,"NEAT1 in Ovarian Cancer: A Key Regulator of Tumor Progression, Follicular Fluid Dynamics, and Therapeutic Resistance.",2025,"Luiza Dias (Department of Biology, College of Arts and Sciences, Appalachian State University, Boone, NC, U.S.A.); Chi-Wei Chen (Department of Biology, College of Arts and Sciences, Appalachian State University, Boone, NC, U.S.A.)",Not Available
40037502,Advancing Glioblastoma Therapy: Learning From the Past and Innovations for the Future.,2025,"Mandeep Rana (School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei 110, Taiwan.); Ke-Chi Liou (School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei 110, Taiwan.); Amandeep Thakur (School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei 110, Taiwan.); Kunal Nepali (School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei 110, Taiwan; TMU Research Center for Drug Discovery, Taipei Medical University, Taipei 110, Taiwan; Ph.D. Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei 110, Taiwan. Electronic address: nepali@tmu.edu.tw.); Jing-Ping Liou (School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei 110, Taiwan; TMU Research Center for Drug Discovery, Taipei Medical University, Taipei 110, Taiwan; Ph.D. Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei 110, Taiwan. Electronic address: jpl@tmu.edu.tw.)",Not Available
40037361,Realigned transsulfuration drives BRAF-V600E-targeted therapy resistance in melanoma.,2025,"Mihály Cserepes (Department of Experimental Pharmacology and the National Tumor Biology Laboratory, National Institute of Oncology, Budapest, 1122, Hungary.); József Tóvári (Department of Experimental Pharmacology and the National Tumor Biology Laboratory, National Institute of Oncology, Budapest, 1122, Hungary.)",Not Available
